reports
Maurel & Prom : Activité T1 2024
PARIS--(BUSINESS WIRE)-- Regulatory News: Maurel & Prom (Paris:MAU): Production en part M&P au T1 2024 : 38 305 bep/j, en hausse de 13% par rapport au T4 2023 Production d’huile en part M&P de 15 499 b/j au Gabon, en augmentation de 8% par rapport au T4 2023 Production d’huile en part M&P de 4 634 b/j en Angola, en hausse de 2% par rapport au T4 2023 Production de gaz en part M&P de 76,9 Mpc/j en Tanzanie, en augmentation de 34% par rapport au T4 2023 Production d’huile en part M&P de 5 353 b/j au Venezuela, stable par rapport au T4 2023 Chiffre d’affaires de 212 M$ au T...
- ING Helpdesk
- Thomas Vranken
Fagron Growth engine keeps running
We updated our model following Fagron's recent 1Q24 update. While our prior estimates for FY24 and beyond largely remain in place, we pay special attention to Fagron's North American compounding services (CS) business (Boston/Wichita + Anazao), as well as the impact of the recent Polish regulatory change. Overall, our valuation continues to point to a TP of € 22, hence we maintain a Buy rating.
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Wim Lewi
Fagron publishes agenda for 2024 annual shareholders meeting and extra...
Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board of Directors of Fagron NV invites shareholders to attend Fagron’s annual general meeting of shareholders and the extraordinary general meeting of shareholders on Monday 13 May 2024. AgendaThe agenda includes the discussion of the annual report, the approval of the annual financial stateme...
- Thomas Vranken
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 04/11/2024
Waga Energy offers an innovative start-up profile in the utilities sector: i/ disruptive technology in biogas treatment, ii/ established competitive advantages, iii/ positioning on a market with strong potential (>20,000 landfills) and iv/ a robust business model based on recurring revenues. At its CMD in February 2024, the company reconfirmed its ambitions for 2026 set out at the IPO (contracts for 4 TWh and recurring revenues of € 200m). The financing secured in Q1 2024 (€ 112m base...
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 11/04/2024
Waga Energy propose un profil de start-up innovante dans le secteur des utilities : i/ une technologie disruptive pour le traitement du biogaz, ii/ des avantages compétitifs établis, iii/ un positionnement sur un marché à fort potentiel (>20 000 décharges) et iv/ un modèle robuste de revenus récurrents. La société a reconfirmé lors du CMD en février 2024 ses ambitions à horizon 2026 annoncées au moment de son IPO (signature de 4 TWh et CA récurrent de 200 M€). Fort des financements ob...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Thomas Vranken
- Wim Lewi
- Robert Jan Vos
- Salome Charamalet
Fagron N.V. : Strong set of Q1 2024 results, 1.5% beat on consensus
>+14.9% of CER revenue growth, driven by strong EMEA and North America - In EMEA, Fagron reported revenue growth 10.3% higher than Q1 2023 (revenue at CER) with a 7% miss on beat (css: € 74.6m) driven by Compounding Services (+32.4%) and partly offset by Brands and Essentials (-3.9% and +3.5%). B&E reflects the impact of the new reimbursement system in Poland, mostly offset by solid performance in other countries. Compounding Services revenue growth of 32.4% (CER) is ...
- Thomas Vranken
Fagron FIRST LOOK: Solid 1Q24 results, EMEA outperforms expectations
Fagron's 1Q24 revenue shows strong performance in key regions with topline reaching € 209m (+15% y/y), driven by sustained high growth in N-Am's compounding activities and the Polish regulatory impact being offset by other countries in EMEA. We maintain our € 22.0 price target and Buy rating.
Record revenue of €209 million in first quarter reflecting 15% topline...
Record revenue of €209 million in first quarter reflecting 15% topline growth Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024. Key Highlights Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regionsOrganic growth at CER of 12.3% reflects the ...
Recordomzet van €209 miljoen in eerste kwartaal en 15% omzetgroei
Recordomzet van €209 miljoen in eerste kwartaal en 15% omzetgroei Gereglementeerde informatie - voorwetenschapNazareth (België)/Rotterdam (Nederland), 11 april 2024 – 7u CET Recordomzet van €209 miljoen in eerste kwartaal en 15% omzetgroei Fagron, de toonaangevende mondiale speler in farmaceutische bereidingen, publiceert vandaag haar kwartaalresultaten voor de periode eindigend 31 maart 2024. Kernpunten Omzetgroei versnelde naar 15,3% gerapporteerde groei (14,9% tegen CER) resulterend in omzet van €209,2 miljoen, gedreven door alle regio’sOrganische omzetgroei van 12,3% tegen CER refle...
- Frank Claassen
Fagron - A flying start
• The Q1-24 organic growth of 12% nicely exceeded our 10%, driven by a strong performance in compounding services in both US and EMEA.• Fagron can comfortably reiterate its FY24 guidance of high single digit organic growth. We see room to slightly increase our estimates by 1-2%.• We reiterate our Buy and our TP of EUR 23, based on our 2025E SOTP and backed by our DCF.
Cellectis publie une nouvelle approche d'édition intronique pour le tr...
Cellectis publie une nouvelle approche d'édition intronique pour le traitement des maladies métaboliques congénitales par des cellules souches hématopoïétiques modifiées NEW YORK, 10 avr. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN® pour développer de potentielles thérapies innovantes pour le traitement de maladies graves, a annoncé aujourd'hui la publication d'un article scientifique dans Molecular Therapy, démontrant que l'édition d'introns par TALE...
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Tre...
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs) enables transgene expression restricted to the myeloi...
Maurel & Prom : Informations concernant l'Assemblée générale ordinaire...
PARIS--(BUSINESS WIRE)-- Regulatory News: Les actionnaires de la société Établissements Maurel & Prom S.A. (Paris:MAU) (la "Société") sont avisés qu'une assemblée générale ordinaire se tiendra, sur première convocation, le mardi 28 mai 2024, à 10 heures, 9 avenue Hoche, 75008 Paris, France. Modalités de mise à disposition des documents préparatoires Un avis de réunion a été publié au Bulletin des Annonces Légales Obligatoires (« BALO ») du 10 avril 2024 et contient l'ordre du jour et les projets de résolutions qui seront soumis à l’Assemblée Générale. Ce document ainsi que le rapport du ...
McPhy Energy: Proposed transfer of the listing of McPhy shares on Euro...
McPhy Energy: Proposed transfer of the listing of McPhy shares on Euronext Growth Paris Grenoble, April 10, 2024 - 6:00 pm CEST – The Board of Directors of McPhy Energy (the “Company”), meeting on April 9, 2024, decided to submit to the next Combined Shareholders' Meeting, to be held on May 30, 2024, in its ordinary part, for approval the proposed transfer of the Company's shares listing from the regulated market of Euronext Paris (compartment C) to the organized multilateral trading facility of Euronext Growth Paris. Reasons for the proposed transfer This proposed transfer...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.